Sekkei Bio has closed its Series A round, co-led by Tenshi Pharmaceuticals and distinguished investor Ashish Kacholia, with participation from deep-tech investor Manish Gandhi.
The company is building a platform-driven biologics discovery engine focused on diabetes and metabolic diseases — including a promising once-a-day oral insulin pill that could meaningfully shift accessibility and adherence for patients worldwide.
This raise comes at a time when India is steadily strengthening its deep-tech foundation. With initiatives such as the formation of a national DeepTech Advisory Board, investor interest in IP-led innovation, frontier science, and R&D-heavy ventures continues to grow.
Done Deal Edge
Through Done Deal, Sekkei Bio engaged with a curated pool of deep-tech and healthcare investors, generating strong inbound and outbound interest. Multiple high-intent conversations were initiated with biotech-focused VCs, pharma strategics, and long-horizon angels aligned with Sekkei’s scientific direction.
These interactions helped the founders gauge investor appetite, sharpen positioning, and ultimately connect with the partners who co-led and supported this round.
Importantly, several investors who engaged with Sekkei via Done Deal have chosen to actively track the company. While they didn’t participate in this round, they have expressed intent to revisit the opportunity in future fundraises, giving Sekkei a strong forward pipeline of aligned capital.
This engagement is a testament to the increasing depth of India’s deep-tech investor ecosystem — and how structured access to the right conversations accelerates outcomes for complex, science-led companies.
The Journey to Funding
The Series A funding will enable Sekkei to:
- Advance its oral insulin program toward clinical development
- Strengthen platform capabilities across biologics design and engineering
- Expand its scientific and translational team
- Accelerate regulatory and R&D pathways
The co-lead investors bring complementary deep-tech and healthcare expertise, along with long-term conviction required to back frontier-science ventures.
Done Deal: Empowering Deep-Tech Fundraises
At Done Deal, we focus on enabling the right strategic conversations, not just introducing capital. Our platform supports innovation-driven teams like Sekkei with access to investors who understand long timelines, scientific risk, and global potential.
If you're building breakthrough science — or know someone who is — join the Done Deal network and let the right opportunities find you.
.svg){kind=icon}